The 2017 Hormone Therapy Position Statement of The North American Menopause Society

The North American Menopause Society 2017 Hormone Therapy Position Statement Advisory Panel

Disclosures

The North American Menopause Society (NAMS). 2018;24(7):728-753. 

In This Article

Sarcopenia

Frailty is associated with AEs such as falls, hospitalization, disability, and death.[136] Skeletal muscle has been shown to have ERs, but there is a paucity of studies evaluating the interplay between estrogen and muscle. The regulation of energy intake and expenditure by estrogens in women has not been well studied, with limited basic and preclinical evidence supporting the concept that the loss of estrogen because of menopause or oophorectomy disrupts energy balance through decreases in resting energy expenditure and physical activity.[137]

Reviews of preclinical studies and limited clinical studies of HT in postmenopausal women suggest a benefit on maintaining or increasing muscle mass and related connective tissue, improving strength and improving posttraumatic or postatro-phy muscle recovery when combined with exercise.[138–140]

Key Points

  • Development of frailty with aging is a health risk.

  • Sarcopenia and osteoporosis are related to aging, estrogen depletion, and the menopause transition. Intervention to improve bioenergetics and prevent loss of muscle mass, strength, and performance is needed.

  • Preclinical studies suggest a possible benefit of ET when combined with exercise to prevent the loss of muscle mass, strength, and performance.

Comments

3090D553-9492-4563-8681-AD288FA52ACE

processing....